



The Synthetic Gene Therapy Company

Eukarÿs winner of the Corporate LiveWire Award for Innovation & Excellence 2020



EUKARÿS

2020 Award Winner

Most Innovative in Gene Therapy

Evry-Courcouronnes, Thursday 13 August 2020,

Eukarÿs is pleased to announce today that it has won the Innovation & Excellence Award 2020 awarded by Corporate LiveWire. This Prize recognizes Eukarÿs innovations in the field of synthetic gene therapy, as well as more recently in synthetic gene vaccination.

About Eukarÿs

Eukarÿs is a French biotechnology company from the Biocluster of the Genopole of Evry and affiliated to the Medicen Competitiveness Cluster which is developing a radically innovative non-viral approach to synthetic gene therapy, recently extended to synthetic gene vaccination. Synthetic gene therapy is designed to be usable for the majority of human diseases and to provide solutions to the challenges of safety, tolerance, immunogenicity and production costs faced by existing gene therapy technologies. It operates the C3P3 system, the first, and to date the only, artificial eukaryotic C3P3 expression system invented and patented by Eukarÿs, as well as gene assembly technologies invented and developed by Eukarÿs.

Contact Eukarÿs SAS | Genopole Campus 3 | 4 rue Pierre Fontaine | 91000 Evry-Courcouronnes, France | contact@eukarys.com | www.eukarys.com